共 183 条
[11]
Weber JS(2020)Moving towards personalized treatments of immune-related adverse events Nat Rev Clin Oncol 3 39-567
[12]
Kahler KC(2015)Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma J Immunother Cancer 4 e180798-1031
[13]
Hauschild A(2018)Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials JAMA Oncol 2 e192535-131
[14]
Khan S(2019)Estimation of the percentage of us patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs JAMA Netw Open 515 563-1563
[15]
Khan SA(2014)Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 108 1022-1477
[16]
Luo X(2017)Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma Cancer Sci 5 351-73
[17]
Faje AT(2018)Cytokines, chemokines, and other biomarkers of response for checkpoint inhibitor therapy in skin cancer Front Med (Lausanne) 37 131-2758
[18]
Lawrence D(2019)Biomarkers to predict immune-related adverse events with checkpoint inhibitors J Clin Oncol 16 94-4029
[19]
Flaherty K(2018)Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade J Transl Med 25 1557-720
[20]
Arbour KC(2019)Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1–based immunotherapy Clin Cancer Res 111 1468-64